Artificial Intelligence Pioneer Dr. Randy Goebel Joins CB2 Insights to Advance its Predictive Insights Platform

Globally-Recognized Machine Learning Expert Joins as Senior Advisor to Data Insights Division

TORONTO, March 14, 2019 (GLOBE NEWSWIRE) — CB2 Insights (“CB2” or the “Company”) (CSE:CBII) a leading global provider of predictive analytics tools, data-driven software and comprehensive services across the medical cannabis value chain, today announced that Dr. Randy Goebel, PhD. will join the Company as a Senior Advisor to its Data Insights division to further advance its predictive analytics tools and insights capabilities.

Dr. Goebel is a professor of Computing Science at the University of Alberta as well as one of the founders and a current researcher at the Alberta Machine Intelligence Institute. He was instrumental in bringing Google’s DeepMind research centre to Canada and is actively involved in academic and industrial projects in Europe and Japan. Dr. Goebel also sits on the advisory boards for the German Research Centre for AI, the Japan Science and Technology Agency and the Japanese National Institute for Informatics.

There is no question that there is an urgent need for more robust usable data systems within the medical cannabis space. I am excited to help CB2 Insights advance their platform to better exploit the critical data they ingest every day and explore cannabinoid therapy in a way that has not previously been done.

Dr. Randy Goebel, PhD

CB2 Insights currently evaluates approximately 65,000 patients annually through its clinic network and handles millions of clinically-validated data points that work to advance the understanding of the efficacy and risks associated with cannabinoid therapy. Moving forward, leveraging that data to create new predictive analytics tools aimed at providing a deeper level of insight to a wealth of stakeholders is key to mainstreaming cannabis into traditional healthcare.

When it comes to artificial intelligence and machine learning, there are few minds as well respected as Dr. Goebel. We are proud of how far we have come to bring about a new level of research and data integrity to the medical cannabis industry and to now have someone of Dr. Goebel’s prominence to enhance that foundation is both humbling and exciting.

Prad Sekar, CEO, CB2 Insights

CB2 Insights’ core mission is to guide cannabis therapy into traditional healthcare, in part through bringing Real-World Evidence and healthcare protocols to the cannabis industry. With Dr. Goebel at the helm of the Company’s Data Advisory team, this will bolster CB2 Insights’ ability to achieve this mission. Dr. Goebel will work with the CB2 Insights team on platform architecture and design enhancements to help serve a variety of new stakeholders to the Company such as regulatory bodies, government agencies, researchers and pharmaceutical companies from the robust set of clinically-led data collected through CB2 Insights’ other business units.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.

For more information please visit

Original Press Release

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter